Not recommended for primary treatment of psychotic illness. Should not be used alone for treatment of sleep disorder associated with depression. Pre-existing depression may be unmasked during benzodiazepine use. Suicide may be precipitated in such patients. Lower dose also recommended in chronic respiratory insufficiency due to risk of respiratory depression. Use of lormetazepam and other benzodiazepines may lead to development of physical and psychological dependence upon these products. Risk of dependence increases with dose and duration of treatment; also greater in history of alcohol or drug abuse (use extreme caution). Once physical dependence has developed, abrupt termination of treatment will be accompanied by withdrawal symptoms (it is recommended that dosage is gradually decreased). Rebound insomnia may occur on withdrawal of treatment. Reactions like restlessness, agitation, irritability, aggressiveness, delusion, rages, nightmares, hallucinations, psychoses, inappropriate, abnormal behavior and other adverse behavioral effects are known to occur when using benzodiazepines. Should this occur, use should be discontinued. These reactions are more likely to occur in children and the elderly, as well as in organic brain syndrome.